"Australian researchers sought to assess the baseline prevalence of fever following the 2010 ban on CSL’s Fluvax in children under five but the information was not available in English language journals."
"The review found that following one dose of TIV, the median average weekly risk of any fever (≥37.5 degrees Celsius) was 26% in unpublished trials compared to 8.2% in published papers."
Medical Observer,
Neil Bramwell, 30th Sept 2013